阿托伐他汀对高脂血症患者血小板聚集反应的影响

观察降血脂药阿托伐他汀作用于高脂血症患者的血小板聚集反应。测试全血血小板聚集对各种诱导剂的反应性及实验的重复性 ,并选择胶原作为诱导剂进行全血血小板聚集反应检测。 30个高脂血症患者接受为期16周的治疗 ,用药剂量递增 ,从每日用药 10、2 0、40mg ,到 80mg ,均分别用药 4周 ,直至患者血脂水平达到靶水平以下。分别在最大剂量用药期及停药后 4周检测患者的血小板聚集反应、血小板计数、平均血小板体积、总胆固醇、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇及甘油三酯水平。总胆固醇、低密度脂蛋白胆固醇及甘油三酯水平在停药后显著回升 (5 .0± 1.1、3.0± 1.0、2 .2± 3.3mmol/L比 9.0± 3.1、6 .8± 1.5、5 .0± 12 .4mmol/L ,P <0 .0 0 1)。与停药后 4周相比 ,在最大剂量用药期 ,患者全血血小板聚集反应显著降低 (自 19.0± 3.1Ω降至 17.1± 4.6Ω ,P <0 .0 5 ) ,而高密度脂蛋白胆固醇、血小板计数及平均血小板体积不受影响。表明阿托伐他汀能有效降低高脂血症患者的血脂水平及改善血小板聚集功能。

Relationship between obesity and cardiovascular risk factors in elderly Chinese subjects

OBJECTIVE: To investigate the relative effects of degree and distribution of body fat with several cardiovascular disease (CVD) risk factors in elderly Chinese subjects. METHODS: One hundred and thirty-five elderly Chinese individuals (age range, 60-65 y) without any history of significant renal, hepatic or cardiac disease were recruited. Seated blood pressure, anthropometric and fasting plasma biochemical parameters were measured. Student's t-test was used to compare the differences in biochemical and anthropometric markers between cohorts. RESULTS: Males were heavier (64.6 +/- 8.6, 57.2 +/- 8.2kg, P